Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 112, Issue 39, Pages E5381-E5390
Publisher
Proceedings of the National Academy of Sciences
Online
2015-09-09
DOI
10.1073/pnas.1515281112
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib
- (2015) Justin F. Gainor et al. Journal of Thoracic Oncology
- Using ancient protein kinases to unravel a modern cancer drug's mechanism
- (2015) C. Wilson et al. SCIENCE
- Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
- (2014) Zheng Zhao et al. ACS Chemical Biology
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
- (2014) Matthew S. Zabriskie et al. CANCER CELL
- Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
- (2014) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
- (2014) R. Katayama et al. CLINICAL CANCER RESEARCH
- Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion-Positive Cancer
- (2014) R. Katayama et al. CLINICAL CANCER RESEARCH
- POVME 2.0: An Enhanced Tool for Determining Pocket Shape and Volume Characteristics
- (2014) Jacob D. Durrant et al. Journal of Chemical Theory and Computation
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
- (2014) Shirish M Gadgeel et al. LANCET ONCOLOGY
- Acquired resistance to TKIs in solid tumours: learning from lung cancer
- (2014) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- Molecular Recognition and Ligand Association
- (2013) Riccardo Baron et al. Annual Review of Physical Chemistry
- Exploring the role of receptor flexibility in structure-based drug discovery
- (2013) Ferran Feixas et al. BIOPHYSICAL CHEMISTRY
- Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain
- (2013) S. Soverini et al. BLOOD
- Identification of Type II Inhibitors Targeting BRAF Using Privileged Pharmacophores
- (2013) Qingwen Zhang et al. Chemical Biology & Drug Design
- Molecular Pathways: ROS1 Fusion Proteins in Cancer
- (2013) K. D. Davies et al. CLINICAL CANCER RESEARCH
- PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data
- (2013) Daniel R. Roe et al. Journal of Chemical Theory and Computation
- ALKin Lung Cancer: Past, Present, and Future
- (2013) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- The quest to overcome resistance to EGFR-targeted therapies in cancer
- (2013) Curtis R Chong et al. NATURE MEDICINE
- Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1
- (2013) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mouse Model for ROS1-Rearranged Lung Cancer
- (2013) Yasuhito Arai et al. PLoS One
- Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target
- (2013) A. Saborowski et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins
- (2013) M. A. Davare et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Biomolecular Simulation: A Computational Microscope for Molecular Biology
- (2012) Ron O. Dror et al. Annual Review of Biophysics
- Abstract 4920: Integrative identification of stochastically activated signaling sub-networks in individual cancer cells
- (2012) Iadevaia Sergio et al. CANCER RESEARCH
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase
- (2012) Linda F. Epstein et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Unusual Arginine Formations in Protein Function and Assembly: Rings, Strings, and Stacks
- (2012) Marco A. C. Neves et al. JOURNAL OF PHYSICAL CHEMISTRY B
- Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer
- (2012) Leow Pay Chin et al. Journal of Thoracic Oncology
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- (2012) Catherine C. Smith et al. NATURE
- Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance
- (2012) C. M. Lovly et al. Science Translational Medicine
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- (2011) Hiroshi Sakamoto et al. CANCER CELL
- ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
- (2011) J. M. Heuckmann et al. CLINICAL CANCER RESEARCH
- Quinoline as a Privileged Scaffold in Cancer Drug Discovery
- (2011) V. R. Solomon et al. CURRENT MEDICINAL CHEMISTRY
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
- (2011) J. Jean Cui et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment
- (2011) E. Grande et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive analysis of kinase inhibitor selectivity
- (2011) Mindy I Davis et al. NATURE BIOTECHNOLOGY
- Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia
- (2010) T. O'Hare et al. CLINICAL CANCER RESEARCH
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for accurate EC50/IC50 estimation
- (2010) J. L. Sebaugh PHARMACEUTICAL STATISTICS
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
- (2009) F. Qian et al. CANCER RESEARCH
- Perspectives on the development of imatinib and the future of cancer research
- (2009) Brian J Druker NATURE MEDICINE
- An improved relaxed complex scheme for receptor flexibility in computer-aided drug design
- (2008) Rommie E. Amaro et al. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
- Determination of Alkali and Halide Monovalent Ion Parameters for Use in Explicitly Solvated Biomolecular Simulations
- (2008) In Suk Joung et al. JOURNAL OF PHYSICAL CHEMISTRY B
- A conserved protonation-dependent switch controls drug binding in the Abl kinase
- (2008) Y. Shan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now